摘要
目的 研究中药复方８６１对肝星状细胞ＮＦ－κＢ活性的影响。方法 将５ｍｇ／ｍｌ的复方８６１加入体外培养的大鼠肝星状细胞系作用４８ｈ。 ＮＦ－κＢ活性的检测采用凝胶电泳移动抑制法，细胞培养液中细胞因子的检测采用ＥＬＩＳＡ法，细胞凋亡采用流式细胞仪和ＴＵＮＥＬ法检测。结果 复方８６１作用使体外培养的肝星状细胞ＮＦ－κＢ结合活性比未加药的空白对照组显著减弱，细胞培养液中的ＩＬ－６和ｓＩＣＡＭ水平减低（Ｐ＜０．０５），星状细胞凋亡增加（Ｐ＜０．０１）。结论 复方８６１显著抑制体外培养的肝星状细胞ＮＦ－κＢ活性可能为治疗肝纤维化中的重要机理之一。
Objective: To investigate the effect of Cpd 861 on nuclear factor-kappa B (NF-kB) binding activity of hepatic stellate cells (HSC) in vitro. Methods The study was oboed out on the culture of hepatic stellate cell line, 5mg/ml of Cpd 861 was added and incubated for 48 hours. NF-κB binding activity was evaluated by electrophoretic mobility shift assays. IL-6 and sICAM-1 levels in the cultured supernatant were detected by ELISA. Cell apoptosis was detected by flow cytometry and TUNEL. Results Cpd 861 suppressed the binding activity of NF-kB in HSCs compared with the control group. Moreover, IL-6 and sICAM-1 levels in the cultured supernatant were decreased (P<0.05) and apoptosis rate of HSCs was increased after Cpd 861 incubation (p<0.01). Conclusions The inhibitory effect on NF-kB binding activity might be part of the cellular mechanism of Cpd 861 to treat liver fibrosis.
出处
《中华肝脏病杂志》
CAS
CSCD
2001年第2期73-74,共2页
Chinese Journal of Hepatology
